These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 23222532)
1. Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review. Fleming ST; Hamilton AS; Sabatino SA; Kimmick GG; Wu XC; Owen JB; Huang B; Hwang W; Med Care; 2014 Sep; 52(9):e58-64. PubMed ID: 23222532 [TBL] [Abstract][Full Text] [Related]
2. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study. Fleming ST; Kimmick GG; Sabatino SA; Cress RD; Wu XC; Trentham-Dietz A; Huang B; Hwang W; Liff JM; Ann Epidemiol; 2012 Nov; 22(11):807-13. PubMed ID: 22948184 [TBL] [Abstract][Full Text] [Related]
3. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973 [TBL] [Abstract][Full Text] [Related]
4. Comparison of SEER Treatment Data With Medicare Claims. Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121 [TBL] [Abstract][Full Text] [Related]
5. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry. Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033 [TBL] [Abstract][Full Text] [Related]
6. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409 [TBL] [Abstract][Full Text] [Related]
7. Construct validity of medicare chemotherapy claims: the case of 5FU. Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793 [TBL] [Abstract][Full Text] [Related]
8. Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study. Goldsbury DE; Smith DP; Armstrong BK; O'Connell DL BMC Health Serv Res; 2011 Oct; 11():253. PubMed ID: 21978077 [TBL] [Abstract][Full Text] [Related]
9. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Klabunde CN; Harlan LC; Warren JL Med Care; 2006 Oct; 44(10):921-8. PubMed ID: 17001263 [TBL] [Abstract][Full Text] [Related]
10. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database. Wang K; Sheets NC; Basak R; Chen RC Cancer; 2016 Oct; 122(19):3069-74. PubMed ID: 27352280 [TBL] [Abstract][Full Text] [Related]
11. Claims data linked to hospital registry data enhance evaluation of the quality of care of breast cancer. Meguerditchian AN; Stewart A; Roistacher J; Watroba N; Cropp M; Edge SB J Surg Oncol; 2010 Jun; 101(7):593-9. PubMed ID: 20461766 [TBL] [Abstract][Full Text] [Related]
12. Utility of the SEER-Medicare data to identify chemotherapy use. Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169 [TBL] [Abstract][Full Text] [Related]
14. Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data. Lavery JA; Lipitz-Snyderman A; Li DG; Bach PB; Panageas KS JCO Clin Cancer Inform; 2019 Feb; 3():1-24. PubMed ID: 30715928 [TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer. Kuo YF; Goodwin JS; Shahinian VB BMC Health Serv Res; 2008 Jul; 8():146. PubMed ID: 18620606 [TBL] [Abstract][Full Text] [Related]
16. Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases. Sathiakumar N; Delzell E; Yun H; Jooste R; Godby K; Falkson C; Yong M; Kilgore ML Med Care; 2017 Dec; 55(12):e144-e149. PubMed ID: 29135778 [TBL] [Abstract][Full Text] [Related]
17. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. Onukwugha E; Yong C; Hussain A; Seal B; Mullins CD BMC Med Res Methodol; 2014 Jan; 14():1. PubMed ID: 24383436 [TBL] [Abstract][Full Text] [Related]
18. Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data. Gore JL; Wright P; Shih V; Chang NN; Noshad S; Rey GG; Wang S; Narayanan S JCO Clin Cancer Inform; 2024 Sep; 8():e2400073. PubMed ID: 39298694 [TBL] [Abstract][Full Text] [Related]
19. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis. Chang SL; Liao JC; Shinghal R J Urol; 2009 Jul; 182(1):255-60; discussion 261. PubMed ID: 19450844 [TBL] [Abstract][Full Text] [Related]
20. Feasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims Database. Hashibe M; Ou JY; Herget K; Bolton D; McPherson J; Hawley C; Garvin J; Doherty JA; Sweeney C JCO Clin Cancer Inform; 2019 Oct; 3():1-10. PubMed ID: 31756128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]